Sana Biotechnology, Inc.
SANA · XNASCIK 1770121fmd_0SG6PBMRY9ECWY1P1DCQGRGA27Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Research and development | 100 | 133 | 249 | 286 | 262 | 216 | 132 |
| Total operating expenses | 141 | 286 | 357 | 273 | 293 | 273 | 250 |
| Operating income | (141) | (286) | (357) | (273) | (293) | (273) | (250) |
| Other non-operating income (expense) | (0) | 0 | 0 | (1) | (0) | (5) | 2 |
| Income before taxes | (138) | (285) | (356) | – | – | – | – |
| Income tax expense | (8) | – | – | – | – | – | 0 |
| Net income from continuing operations | (131) | – | – | – | – | – | – |
| Net income | (131) | (285) | (356) | (269) | (283) | (267) | (244) |